Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR
MA Ortega, O Fraile-Martínez, Á Asúnsolo… - Journal of …, 2020 - Wiley Online Library
Breast cancer is the cancer with the highest prevalence in women and is the number‐one
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …
The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress
A Bahrami, M Khazaei, S Shahidsales… - Journal of cellular …, 2018 - Wiley Online Library
Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR
pathway is among the most frequently dysregulated pathways in patients with BC. The …
pathway is among the most frequently dysregulated pathways in patients with BC. The …
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
E Paplomata, R O'Regan - Therapeutic advances in medical …, 2014 - journals.sagepub.com
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …
PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation
V Ruchi Sharma, G Kumar Gupta… - Current …, 2017 - ingentaconnect.com
Background: The most recurrent and considered second most frequent cause of cancer-
related deaths worldwide in women is the breast cancer. The key to diagnosis is early …
related deaths worldwide in women is the breast cancer. The key to diagnosis is early …
Targeting PI3K/AKT/mTOR signaling pathway in breast cancer
Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
N Dey, P De, B Leyland-Jones - Pharmacology & therapeutics, 2017 - Elsevier
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis
PF McAuliffe, F Meric-Bernstam, GB Mills… - Clinical breast …, 2010 - Elsevier
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression …
(mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression …
Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
SE Ghayad, PA Cohen - Recent patents on anti-cancer drug …, 2010 - ingentaconnect.com
Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
M McKenna, S McGarrigle, GP Pidgeon - Biochimica et Biophysica Acta …, 2018 - Elsevier
Abstract The PI3K/Akt/mTOR pathway plays a role in various oncogenic processes in breast
cancer and key pathway aberrations have been identified which drive the different molecular …
cancer and key pathway aberrations have been identified which drive the different molecular …
[HTML][HTML] PI3K/Akt/mTOR inhibitors in breast cancer
JJX Lee, K Loh, YS Yap - Cancer biology & medicine, 2015 - ncbi.nlm.nih.gov
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition …
(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition …